In the HIMALAYAS randomized, open, active-controlled, phase III comparator study (NCT02052310; n = 1043), roxadustat was not worse than alpha erythropoietin in the treatment of anemia in patients who had recently started treatment with hemodialysis, due to terminal renal failure [12]. Here, EPO is linked to anemia.